Australia: Bionomics closes US$20m IPO of ADS

Bionomics, an Australia-based clinical-stage biopharmaceutical company, has closed its US IPO of 1.622 million American Depositary Shares (ADS), each representing 180 of the company’s ordinary shares of Bionomics. The deal was priced at US$12.35 per ADS. Gross proceeds were approximately US$20m. There is also a 30-day option for the underwriters to purchase up to 243,300…

You must be a HMI Subscriber to view this content.

Subscribe Now »